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Abstract
The major cause of morbidity and mortality in cystic fibrosis (CF) patients is chronic Pseudomonas aeruginosa lung infection.
In a mouse model of P. aeruginosa lung infection mimicking that in CF patients, the effects of ginseng treatment on cytokine
responses and the correlation between the changes in cytokine production and the lung pathology were studied. Mice were
challenged with alginate beads containing P. aeruginosa (10 CFUyml). A saline extract of ginseng was injected subcutaneously9
at a dosage of 250 mgykg of body weightyday for 7 days. Saline was used as a placebo control. One week after challenge, a
significantly lower mortality was found in the ginseng treated group (P-0.005). The lung cells from the ginseng treated group
produced more interferon-gamma (IFN-g) (P-0.04) and tumor necrosis factor-alpha (TNF-a) (P-0.03) but less interleukin-4
(IL-4) (P-0.02) with a higher ratio of IFN-gyIL-4 (P-0.004) after 6 andyor 24 h of incubation with specific and non-specific
antigens as compared to the control group. The ginseng treated splenocytes produced more TNF-a (P-0.03) and IFN-g (P(0.05)
than the control spleen cells. Furthermore, a significantly milder lung pathology (P-0.025) and a faster bacterial clearance (P-
0.038) from the lungs were also found in the ginseng treated group compared to the control group. These results indicate a Th1-
like immune response in the mice with P. aeruginosa lung infection after 7 days of ginseng treatment, which is an important
mechanism accounting for ginseng’s favorable action. We therefore believe that Th1 response might benefit the host with P.
aeruginosa lung infection and ginseng treatment might be a promising alternative measure for the treatment of chronic P.
aeruginosa lung infection in CF patients.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Cystic fibrosis (CF) patients are characteristically
susceptible to chronic Pseudomonas aeruginosa lung
infection with increasing ages w1x. The bacteria grow in
alginate biofilm and produce b-lactamase to protect
themselves from the host immune responses and the
action of antibiotics w1–3x. It is, therefore, difficult to
eradicate the chronic P. aeruginosa lung infection with
antibiotic treatment. The recurrent lung infection of P.
aeruginosa will gradually destruct the lung tissues lead-
ing to poor prognosis. Clearly, an alternative and effec-
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tive solution is needed for the control of the infection.
The natural course of chronic P. aeruginosa lung infec-
tion in CF patients or in rat and mouse models is a T
helper type 2 (Th2)-like response w2,4–8x, i.e. the
pronounced antibody response against P. aeruginosa
antigens leads to the formation of immune complexes
in the lung tissues and in turn the infiltration of poly-
morphonuclear leukocytes (PMN) resulting in lung tis-
sue damage. We therefore speculate that a Th1
dominated immune response might favor the host with
chronic P. aeruginosa lung infection.
Previously we have shown that treatment with crude
ginseng extract suppressed serum antibody responses
against P. aeruginosa antigens, decreased IgG1 but
increased IgG2a in serum, reduced mast cell number in
the lung foci of the rat model with chronic P. aeruginosa
lung infection w7–10x. At the same time, the lung
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pathology became milder and the lung bacterial clear-
ance was greatly enhanced w7–10x. However, the mech-
anism behind the favorable actions of ginseng treatment
is unknown. In the present study, ginseng treatment was
conducted to a mouse model of P. aeruginosa lung
infection and the therapeutic effects as well as the
cytokine dichotomy of Th1yTh2 responses in the infec-
tion primed lung cells in the comparison with a control
group were studied.
2. Materials and methods
2.1. Animals
CBAyJ mice: Eighty-six healthy female CBAyJ mice
(M&B Laboratory animals, Ry, Denmark), 11-weeks
old with body weights of 22–30 g were used. The mice
were divided into two groups, 39 mice in the ginseng
treated group and 47 in the control group.
2.2. Challenge strain
Mucoid P. aeruginosa PAO 579 (International Anti-
genic Typing System O: 2y5) w11,12x was used in our
study.
2.2.1. Immobilization of P. aeruginosa in seaweed algin-
ate beads
The method was described previously w13x In brief, 1
ml of the P. aeruginosa bacterial culture was mixed
with 9 ml of seaweed alginate (60% guluronic acid
content) and the mixture was forced once with air
through a cannula into a solution of 0.1 M CaCl in 0.12
M Tris–HCl buffer (pH 7.0). The suspension was
adjusted to yield 10 CFUyml and the yield was con-9
firmed by colony counts.
2.2.2. Preparation of ginseng extract
The ginseng saline extract was prepared using the
method described previously w8x In brief, 2.5 g of Panax
ginseng C.A. Meyer (ginseng) powder (provided kindly
by Millingwang Limited, Jilin, PR China) was mixed
with 100 ml of saline, and then the mixture was heated
and filtered through sterile filter paper twice before use
(final concentration: 25 mg of the equivalent of dry
powder per ml). The concentration of protein in the
ginseng extract was 3.5 mgyml and the level of endo-
toxin-like material was 60 ngyml w8x which is 1660
times lower than the amount of lipopolysaccharide
(LPS) that we used in another study w14x The two
parameters are used as the quality control of the ginseng
extract.
2.3. Treatment protocol
The ginseng treated group: 2.5% of ginseng saline
extract was injected subcutaneously (250 mgykg) once
a day for 7 days. The dosage was decided according to
the results of a pilot study for dosages.
The control group: sterile saline (0.9%) was injected
subcutaneously (10 mlykg) once a day for 7 days as a
placebo control.
2.4. Challenge procedures
At the time of challenge, all mice were anesthetized
by subcutaneous injection of a 1:1 mixture of etomidat
(Janssen, Birkerød, Denmark) and midazolam (Roche,
Hvidovre, Denmark) at a dose of 10 mlykg of body
weight and tracheotomized w15,16x. Intratracheal chal-
lenge with 0.04 ml of P. aeruginosa (10 CFUyml) in9
alginate beads was performed with a bead-tipped needle
w15,16x. The incision was sutured with silk and healed
without any complications. Seven days after challenge,
all animals were killed by using 20% pentobarbital
(DAK, Copenhagen, Denmark) at 2 mlykg body weight.
The challenge and the start of administration of
ginseng or saline were on the same day.
2.5. Macroscopic pathology of the lungs
The macroscopic lung pathology was expressed as
the lung index of macroscopic pathology (LIMP), which
was calculated according to the formula: LIMPsthe
lung area with pathologic changesythe area of the same
side lung (left lung) w7,17x. The lung pathological
changes include lung abscess, atelectasis, consolidation,
hemorrhage, and lung edema. The evaluation was done
blindly.
2.6. Histopathologic scoring of the lungs
The cellular alterations in the lungs were classified as
acute or chronic inflammation by a scoring system based
on the proportion of neutrophils (PMN) and mononu-
clear leukocytes (MN) in the inflammatory foci w18x.
Acute inflammation was defined as an inflammatory
infiltration in which PMNs were predominant (090%
PMNs with(10% MNs), whereas chronic inflammation
was defined as a preponderance of MNs (090% with
(10% PMNs), which included lymphocytes, plasma
cells, and the presence of granulomas w1,18x. Four
scoring groups were assigned microscopically to evalu-
ate the severity of the inflammation, as follows
w7,8,10,18x: (1) normal histology; (2) mild and focal
chronic inflammation; (3) moderate to severe focal
chronic inflammation mixed with areas of normal lung
tissue; and (4) acute inflammation to necrosis or severe
chronic inflammation throughout the lung.
The histopathological evaluations were done in a
double-blind way to avoid bias.
114 Z. Song et al. / Journal of Cystic Fibrosis 2 (2003) 112–119
2.7. Lung bacteriology
The lungs from one-third of the animals in each group
were selected randomly for the quantitative bacteriolog-
ical examination as described previously w15,16x. In
brief, lungs were removed aseptically and homogenized
in 5 ml of PBS. Appropriately diluted samples were
plated on agar plates to determine the number of CFU.
2.8. Preparation of lung and spleen cell suspensions
w15,16x
By the time of killing, mouse lungs were exsangui-
nated by cutting the vena cava inferior and infusing
PBS to the right ventricle. The lungs were then washed
once in the complete RPMI 1640 medium wwith 2%
fetal calf serum (FCS, Biological Industries, Kibbutz
Beit Haemek, Israel), 10 mM of HEPES (Panum Insti-
tute, Denmark), 20 units of penicillinyml, 20 mg of
streptomycinyml, 100 mg of gentamycinyml, 58.4 mg
of L-glutamine and 0.05 mM of 2-mercaptoethanolx.
The lungs were cut into small pieces in 10 ml of the
complete RPMI 1640 medium containing 2 mg of
collagenaseyml (Sigma Chemical Co., St. Louis, USA)
and 50 mg of DNaseyml (Boehringer Mannheim GmbH,
Mannheim, Germany). The lung pieces were incubated
in shaking condition for 1.5 h at 37 8C. Free cell
suspension was obtained by repeated pipetting and by
passing through a 18-G needle followed by a 23-G
needle. The cells were washed 3 times with the complete
RPMI 1640 medium and resuspended in 6 ml of the
complete RPMI 1640 medium with 10% FCS. The cells
were stained with crystal-violet and counted for the cell
concentration, which was adjusted to 2=10 cellsyml.6
Spleens were obtained aseptically and perfused sev-
eral times with 10 ml of 10% FCS-complete RPMI 1640
medium. Erythrocytes were removed by 0.17 M of
NH Cl and washed twice with 10% FCS-complete RPMI4
1640 medium (350 g, 10 min) and resuspended in 5 ml
of 10% FCS-complete RPMI 1640 medium. Number of
the cells were confirmed by counting in trypan blue
(viability )90%) and were adjusted to 4=10 cellsy6
ml.
2.9. Antigens and mitogens
The outer membrane protein (OMP) of P. aeruginosa
was prepared by the following method w15,16x: the P.
aeruginosa sonicate in distilled water was mixed with
20% of Sarkosyl (100 mlyml) and centrifuged in
3000=g for 10 min after 30–60 min of staying in room
temperature. The supernatant was centrifuged again and
washed once with distilled water in 20 000=g for 30
min. The deposition was resuspended in distilled water
and filtered by a syringe filter with a pore size of 0.20
mm.
The final OMP concentration in the medium was 10
mgyml. Concanavalin A (ConA) (Pharmacia Fine
Chemicals AB, Uppsala, Sweden) for non-specific stim-
ulation was employed in a final concentration of 4 mgy
ml. Monoclonal hamster anti-mouse CD3e without
sodium azide (anti-CD3) (Pharmingen, San Diego,
USA) for short stimulation of already activated T-cells
was used in a final concentration of 0.5 mgyml. OMP
and ConA were incubated with the cells for 24 h and
anti-CD3 was incubated with the cells for 6 h. Medium
without antigen or mitogen was used as control for 6 or
24 h. The above time points of antigens or mitogen
stimulation for the cell culture were decided upon the
pilot kinetic studies, in which the time points of 6, 12,
24, 48 and 72 h were tested (data not shown).
2.10. Cytokine production
One hundred microliter of the proper adjusted cell
suspensions were added to each well in round bottomed
micro-titer plates (Nunc, Roskilde, Denmark) and 100
ml of medium with OMP, ConA, anti-CD3 or medium
alone were added to the cells in triplicates w15,16x. Cells
were incubated at 37 8C in a 5% CO . Supernatants2
from the lung cells stimulated with anti-CD3 were
harvested after 6 h of incubation, and the supernatants
from the lung cells stimulated with OMP and ConA
were harvested after 24 h. The samples were kept at
y70 8C until use.
The concentrations of interleukin-4 (IL-4), interferon-
gamma (IFN-g) and tumor necrosis factor-alpha (TNF-
a) in the supernatants were determined by ELISA kits
(Genzyme, Cambridge, USA). IL-4 standard curve range
from 62.5 to 1000 pgyml (sensitivity 10 pgyml), IFN-
g standard curve range from 20 to 1620 pgyml (sensi-
tivity 10 pgyml), and TNF-a standard curve range from
125 to 2000 pgyml (sensitivity 15 pgyml).
2.11. Statistical analysis
Unpaired differences in continuous data were ana-
lyzed by the Mann–Whitney U test and ANOVA test,
and categorical data were compared using the x -test.2
The correlation analysis between the parameters was
performed by the Simple Regression.
3. Results
3.1. Mortality
In the ginseng treated group, 5 out of 39 mice died
from lung infection (12.8%) whereas 21 out of 47 mice
in the control group (44.7%) were dead due to the lung
infection. The difference between the two groups was
significant, P-0.005. The mortality was determined 7
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Fig. 1. Photomicrograph of a section from the base of the left lung in
the control group 7 days after intratracheal challenge with alginate
beads of P. aeruginosa. The photo shows the damage of bronchial
wall and significant infiltration of inflammatory cells in the bronchia
and the lung tissues (HE staining, =250).
Fig. 2. Photomicrograph of a lung section in the control group. The
arrow shows that the alginate beads in the bronchia were surrounded
by numerous PMNs (HE staining, =400).
Fig. 3. Photomicrograph of a lung section from the ginseng treated
group. The photo shows that the inflammatory focus is dominated by
the infiltration of mononuclear leukocytes (HE staining, =400).
Table 1
Histopathological changes in the lung tissues 7 days after intratracheal challenge with P. aeruginosa in alginate beads
Treatment (n) Inflammation Acute-chronicb Score 2a Score 3a Score 4a
Acute (in bronchi)
Ginseng (9) 1 (11%)*** 8 (89%)*** 5 (56%)** 2 (22%) 2 (22%)*
Control (9) 7 (78%) 2 (22%) 0 2 (22%) 7 (78%)
Compared with the control group, *P-0.025, **P-0.01, ***P-0.005.
See Section 2.a
The proportion of PMN:NMs-50%:)50%.b
days after challenge and the death happened mainly 2–
3 days after challenge.
3.2. Pathology
3.2.1. Macroscopic pathology of the lungs
One week after P. aeruginosa lung infection, the
LIMP in the ginseng treated group (ns34) was 0.27
(range: 0.15–0.67) or 0.30"0.11 (mean"S.D.), signif-
icantly lower than that in the control (ns26) group
w0.50 (range: 0.27–0.93), or 0.54"0.21x, Ps0.0001.
Simple Regression analysis showed that the LIMP in
the ginseng treated group was positively correlated with
the lung bacteriology (rs0.78, P-0.02).
3.2.2. Histopathology of the lungs
Nine mice from each group were selected randomly
for histopathological examination. The acute inflamma-
tory response was found mainly in the bronchia, and the
lung tissues around the bronchia were also involved.
The damage of bronchial wall and significant infiltration
of inflammatory cells in the bronchia and the lung
tissues were seen in both groups (Figs. 1 and 2).
However, the inflammatory reaction in the ginseng
treated group was less acute (PMNs-50% and MN)
50%, Fig. 3) and milder compared to the control group
(P-0.025, Table 1).
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Table 2
Cytokine production from the lung cells 7 days after P. aeruginosa lung infection in mice wmedian (range) pgymlx and wmean"S.D. pgymlx
Antigens (time) Ginseng (ns9) Control (ns8) P values
(a) Median (range) pgyml
IFN-g Anti-CD3 (6 h) 120 (40–260) 30 (1–150) -0.04
OMP (24 h) 355 (100–815) 265 (30–570) -0.04
ConA (24 h) 2420 (1530–3330) 2100 (570–2750) )0.1
IL-4 Anti-CD3 (6 h) 75 (30–150) 105 (60–210) -0.02
IFN-gyIL-4 (6 h) 4.00 (0.44–26.00) 0.45 (0.001–1.38) -0.004
ConA (24 h) 115 (30–180) 180 (90–222) -0.018
TNF-a Anti-CD3 (6 h) 120 (40–370) 125 (0–190) )0.2
OMP (24 h) 970 (400–1955) 310 (125–1130) -0.03
ConA (24 h) 1260 (930–1775) 650 (510–890) -0.0002
(b) Mean"S.D. pgyml
IFN-g Anti-CD3 (6 h) 131.11"69.54 64.29"60.24 -0.04
OMP (24 h) 851.11"452.15 511.43"357.04 -0.04
ConA (24 h) 2420.56"621.89 1848.57"749.59 )0.1
IL-4 Anti-CD3 (6 h) 50.33"35.65 105.86"48.15 -0.02
IFN-gyIL-4 (6 h) 7.19"7.09 0.71"0.57 -0.004
ConA (24 h) 106.33"41.76 166.71"44.91 -0.018
TNF-a Anti-CD3 (6 h) 164.44"116.42 95.71"77.27 )0.2
OMP (24 h) 1093.33"445.3 427.86"355.03 -0.03
ConA (24 h) 1307.22"277.23 655.00"146.03 -0.0002
Anti-CD3, anti-CD3 antibody; OMP, outer membrane proteins of P. aeruginosa; ConA, Concanavalin A.
Table 3
Cytokine production from the mouse spleen cells 24 h after incubation
with OMP of P. aeruginosa wmedian (range) pgymlx and wmean"S.D.
pgymlx
Treatment (n) IFN-g TNF-a
(a) median (range) pgyml
Ginseng (9) 2360 (1675–2910) 1430 (410–2510)
Control (8) 1590 (940–3320) 600 (10–1340)
P value (0.05 -0.02
(b) Mean"S.D. pgyml
Ginseng (9) 2365.68"435.37 1366.67"655.84
Control (8) 1567.14"500.39 580.32"462.60
P value (0.05 -0.02
3.2.3. Lung bacteriology
Seven days after intratracheal challenge with alginate
beads containing P. aeruginosa, 9 mice were selected
randomly from each group for the examination of lung
bacteriology. The median lung bacterial count in the
ginseng treated group was 50 (0–12 750) CFUylung,
and in the control group it was 18 300 (0–1 625 000)
CFUylung, P-0.038. The median lung bacterial count
in the ginseng treated group was 365 times lower than
in the control group.
3.2.4. Cytokine production
Nine and eight mice were selected randomly from the
ginseng treated and the control groups, respectively, for
the lung and spleen cytokine examinations.
3.2.4.1. IFN-g. After 6 h of incubation with anti-CD3
antibody and 24 h of culture with OMP of P. aeruginosa,
the production of IFN-g from the ginseng treated lung
cells was significantly higher in the culture supernatant
as compared with the control group (P-0.04, Table 2).
The ratio of IFN-gyIL-4 after 6 h of incubation with
anti-CD3 antibody in the ginseng treated group was
higher than that in the control group (P-0.004). In the
response to ConA after 24 h, no significant difference
was found between the two groups. Higher IFN-g
production was also seen in the ginseng treated spleen
cells (Table 3). Regression analysis showed that the
lung IFN-g level in the ginseng treated group was
negatively correlated with its IL-4 level after 6 h
incubation with anti-CD3 antibody in lung cells (rs
y0.67, P-0.008).
3.2.4.2. TNF-a. No significant difference was found in
TNF-a production from the lung cells after 6 h of
incubation with anti-CD3 antibody. However, 24 h after
culture, TNF-a production from the ginseng treated lung
cells stimulated with ConA (P-0.0002) and OMP (P-
0.03) was increased (Table 2). Higher TNF-a produc-
tion was also seen in the spleen cell culture from the
ginseng treated group (P-0.02) compared to the control
group (Table 3).
3.2.4.3. IL-4. The IL-4 production in the lung cells from
the ginseng treated group was significantly lower than
that from the control group after 6 h of incubation (P-
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0.02) with anti-CD3 antibody (Table 2). After 24 h of
culture with OMP, the IL-4 levels in both lung cells and
spleen cells were below the detection of 62.5 pgyml
(data not shown). The IL-4 response to the stimulation
of ConA in the lung cells from the ginseng treated
group was significantly lower (P-0.018) than that from
the control group (Table 2).
4. Discussion
Ginseng is a well-known Chinese traditional medi-
cine, which has been used in China as a valued herbal
remedy for more than 4000 years w19x. Traditionally,
ginseng is used as a tonic, rejuvenating and revitalizing
agent, whereas currently it has been demonstrated that
ginseng possesses a wide range of pharmaceutical and
therapeutical effects on many systems such as the central
nervous system, cardiovascular system, endocrine sys-
tem and immune system, etc. w19,20x. However, gin-
seng’s potential functions of anti-microorganism
infection are poorly investigated.
Chronic P. aeruginosa lung infection in CF patients
is characterized by a pronounced serum antibody
response against the pathogen and the infiltration of
numerous PMNs in the lung tissues, which have been
shown to be connected to a poor prognosis w1,2,21,22x
and is a Th2-like immune response w6x. Previously we
had shown in a rat model of chronic P. aeruginosa lung
infection that ginseng treatment down-regulated the
excessive antibody response and reduced the severity of
lung pathology w7x. Furthermore, mast cell number in
the lung foci reduced w8,10x and serum IgG2a increased
but IgG1 decreased w7x after ginseng treatment, indicat-
ing a Th1-like response.
In the present study, ginseng treatment induced a
significantly higher IFN-g and TNF-a, but lower IL-4
production and higher ratio of IFN-gyIL-4 in the lung
cells from the mice with P. aeruginosa lung infection,
consistent with a Th1-like response that has been seen
in our previous work. In the IFN-g response, ConA did
not induce a higher IFN-g production in the ginseng
treated lung cells whereas OMP did, indicating such
IFN-g response was a specific one. The significantly
lower mortality seen in the ginseng treated group sug-
gests a strong protection against P. aeruginosa lung
infection due to ginseng treatment. Milder lung pathol-
ogy and a greatly enhanced lung bacterial clearance
found in the ginseng treated group 7 days after intratra-
cheal P. aeruginosa challenge indicate the powerful
modulating effects of ginseng in the bacterial infection.
The positive correlation between lung pathology and
bacteriology in the ginseng treated group indicates a
clear relationship between the pathogen number and the
severity of lung pathology.
Host immune response against microbial infection
could be divided into two different types according to
the activation of T helper cell type and the changes in
cytokine patterns. Th1 response is characterized by the
production of IFN-g and IL-2, which favors cellular
immunity and results in an increase of serum IgG2a
level, whereas Th2 response is associated with the
secretion of IL-4 and IL-5 as well as the activation of
B lymphocytes and mast cells, enhances the develop-
ment of humoral immunity and induces the production
of IgG1 in serum w23–27x. In our rat model of chronic
P. aeruginosa lung infection, higher serum IgG and
IgG1 response and more mast cells in the lung foci were
seen in the placebo control group indicating a Th2-like
response compared to the ginseng treated group w7–10x.
However, ginseng treatment successfully induced a shift
of the immune response from a Th2-like to a Th1-like,
which led to a significantly enhanced bacterial clearance
and milder lung pathology w7–10x. In the present study,
a similar result was found in the mouse model of P.
aeruginosa lung infection as well, and the cytokine
reaction from the lung cells showed a Th1 dominated
cytokine profile in the ginseng treated group, which
might account for the favorable effects of ginseng on
the animals with P. aeruginosa lung infection.
IFN-g is known to inhibit the production of IL-4 and,
therefore, down-regulate the antibody response w23,25–
27x. The negative correlation between IFN-g and IL-4
seen in the ginseng treated group after 6 h of incubation
in our study is consistent with the conclusion. IFN-g is
produced by T lymphocytes and natural killer (NK)
cells w28x and is able to activate the microbicide function
by macrophages and NK cells w28x. Furthermore, IFN-
g can enhance the chemotaxis and phagocytosis of
PMNs to the pathogens w29x. Previously we had found
that ginseng treatment improved the phagocytosis to P.
aeruginosa by PMNs, monocytes and lung macrophages
in rats w30x. Our results also showed a stronger TNF-a
response in the lungs due to ginseng treatment indicating
the activation of phagocytes in the lungs. In vitro study
also demonstrated that ginseng stimulation increased the
TNF-a production from the mouse splenocytes and
macrophages w31x. Yang et al. reported that ginseng
treatment significantly increased the phagocytosis by
macrophages and enhance NK activities in mice w32,33x.
An in vitro investigation of ginseng showed that ginseng
significantly enhanced NK activity and also the anti-
body-dependent cell-mediated cytotoxicity (ADCC) in
the peripheral blood mononuclear cells from both
healthy subjects and patients with chronic fatigue syn-
drome or AIDS w34x. Similar results were also reported
by other authors w35–38x. We speculate that the activat-
ed NK cells and ADCC function might also be involved
in the mechanism of ginseng’s favorable action observed
in our study.
The cytokine results from the ginseng treated spleen
cells might suggest a systemic activation of a Th1-like
response against P. aeruginosa lung infection due to
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ginseng treatment. Our previous results have demonstrat-
ed that the outcome of P. aeruginosa infection in a Th1
responding animal was much better than in a Th2
responder w15,16x, and IFN-g treatment very signifi-
cantly improved the prognosis of P. aeruginosa infected
rats w18,39x. In CF patients, Th1 response can help to
clear the infection and keep better lung functions w6x.
The response of IL-4 from the lung cells after 24 h of
incubation was unfortunately not detectable using ELI-
SA method in the study. The reason might be due to the
consumption of the cells in a longer time of incubation.
In the present study, the favorable therapeutical effects
in the ginseng treated group come from the administra-
tion of a crude ginseng aqueous extract. It has been
known that ginseng contains more than 70 different
kinds of components, such as saponins, polysaccharides,
proteins, fatty acid, and so on w19x. Yet, it is not clear
that which component(s) of ginseng is(are) responsible
for the therapeutical effects found in our study. It is
important to isolate and characterize the active com-
pounds from ginseng for further study.
In summary, ginseng treatment induced a Th1-like
response in the mice with P. aeruginosa lung infection,
which might activate the phagocytes and NK cells to
clear the bacterial infection more effectively, and down-
regulate the antibody response which could reduce the
formation of immune complexes in lungs and results in
less lung tissue damage. We therefore conclude that Th1
response might benefit the host with chronic P. aerugi-
nosa lung infection and ginseng treatment might be a
promising alternative measure for the treatment of chron-
ic P. aeruginosa lung infection in CF patients. To clarify
the active compounds in ginseng, further study is
needed.
References
w1x Hoiby N, Frederiksen B. Microbiology of cystic fibrosis. In:
Hodson ME, Geddes DM, editors. Cystic fibrosis. London:
Arnold, 2000. p. 83–107.
w2x Hoiby N, Krogh JH, Moser C, Song Z, Ciofu O, Kharazmi A.
Pseudomonas aeruginosa and the in vitro and in vivo biofilm
mode of growth. Microbes Infect 2001;3(1):23–35.
w3x Giwercman B, Jensen ET, Hoiby N, Kharazmi A, Costerton
JW. Induction of beta-lactamase production in Pseudomonas
aeruginosa biofilm. Antimicrob Agents Chemother
1991;35(5):1008–10.
w4x Wu H, Song Z, Givskov M, et al. Pseudomonas aeruginosa
mutations in lasI and rhlI quorum sensing systems result in
milder chronic lung infection. Microbiology 2001;147:1105–
13.
w5x Johansen HK. Potential of preventing Pseudomonas aeruginosa
lung infections in cystic fibrosis patients: experimental studies
in animals. APMIS Suppl 1996;63:5–42.
w6x Moser C, Kjaergaard S, Pressler T, Kharazmi A, Koch C,
Hoiby N. The immune response to chronic Pseudomonas
aeruginosa lung infection in cystic fibrosis patients is predom-
inantly of the Th2 type. APMIS 2000;108(5):329–35.
w7x Song Z, Kharazmi A, Wu H, et al. Effects of ginseng treatment
on neutrophil chemiluminescence and immunoglobulin G sub-
classes in a rat model of chronic Pseudomonas aeruginosa
pneumonia. Clin Diagn Lab Immunol 1998;5(6):882–7.
w8x Song Z, Johansen HK, Faber V, et al. Ginseng treatment
reduces bacterial load and lung pathology in chronic Pseudo-
monas aeruginosa pneumonia in rats. Antimicrob Agents
Chemother 1997;41(5):961–4.
w9x Song Z, Johansen HK, Faber V. Effects of subcutaneous
injection with different doses of ginseng on the rat model of
chronic Pseudomonas aeruginosa pneumonia. Zhongguo
Zhong Xi Yi Jie He Za Zhi 1998;18(9):546–9.
w10x Song ZJ, Johansen HK, Faber V, Hoiby N. Ginseng treatment
enhances bacterial clearance and decreases lung pathology in
athymic rats with chronic P. aeruginosa pneumonia. APMIS
1997;105(6):438–44.
w11x Govan JR, Fyfe JA, Baker NR. Heterogeneity and reduction
in pulmonary clearance of mucoid Pseudomonas aeruginosa.
Rev Infect Dis 1983;5(Suppl 5):S874–S879.
w12x Govan JR, Fyfe JA. Mucoid Pseudomonas aeruginosa and
cystic fibrosis: resistance of the mucoid from to carbenicillin,
flucloxacillin and tobramycin and the isolation of mucoid
variants in vitro. J Antimicrob Chemother 1978;4(3):233–40.
w13x Pedersen SS, Shand GH, Hansen BL, Hansen GN. Induction
of experimental chronic Pseudomonas aeruginosa lung infec-
tion with P. aeruginosa entrapped in alginate microspheres.
APMIS 1990;98(3):203–11.
w14x Lange KH, Hougen HP, Hoiby N, Fomsgaard A, Rygaard J,
Johansen HK. Experimental chronic Pseudomonas aeruginosa
lung infection in rats. Non-specific stimulation with LPS
reduces lethality as efficiently as specific immunization.
APMIS 1995;103(5):367–74.
w15x Moser C, Hougen HP, Song Z, Rygaard J, Kharazmi A, Hoiby
N. Early immune response in susceptible and resistant mice
strains with chronic Pseudomonas aeruginosa lung infection
determines the type of T-helper cell response. APMIS
1999;107(12):1093–100.
w16x Moser C, Johansen HK, Song Z, Hougen HP, Rygaard J, Hoiby
N. Chronic Pseudomonas aeruginosa lung infection is more
severe in Th2 responding BALByc mice compared to Th1
responding C3HyHeN mice. APMIS 1997;105(11):838–42.
w17x Grimwood K, To M, Rabin HR, Woods DE. Inhibition of
Pseudomonas aeruginosa exoenzyme expression by subinhi-
bitory antibiotic concentrations. Antimicrob Agents Chemother
1989;33(1):41–7.
w18x Johansen HK, Espersen F, Cryz SJ Jr, et al. Immunization with
Pseudomonas aeruginosa vaccines and adjuvant can modulate
the type of inflammatory response subsequent to infection.
Infect Immun 1994;62(8):3146–55.
w19x Huang KC. The pharmacology of Chinese herbs. 1st ed. Boca
Raton: CRC Press Inc, 1993.
w20x Liu CX, Xiao PG. Recent advances on ginseng research in
China. J Ethnopharmacol 1992;36(1):27–38.
w21x Doring G, Bellon G, Knight R. Immunology of cystic fibrosis.
In: Hodson ME, Geddes DM, editors. Cystic fibrosis. London:
Arnold, 2000. p. 109–40.
w22x Cripps AW, Dunkley ML, Clancy RL, Kyd J. Pulmonary
immunity to Pseudomonas aeruginosa. Immunol Cell Biol
1995;73(5):418–24.
w23x Belardelli F. Role of interferons and other cytokines in the
regulation of the immune response. APMIS 1995;103(3):161–
79.
w24x De Franco M, Gille-Perramant MF, Mevel JC, Couderc J. T
helper subset involvement in two high antibody responder lines
of mice (Biozzi mice): HI (susceptible) and HII (resistant) to
collagen-induced arthritis. Eur J Immunol 1995;25(1):132–6.
w25x Romagnani S. Th1yTh2 cells. Inflamm Bowel Dis
1999;5(4):285–94.
119Z. Song et al. / Journal of Cystic Fibrosis 2 (2003) 112–119
w26x Infante-Duarte C, Kamradt T. Th1yTh2 balance in infection.
Springer Semin Immunopathol 1999;21(3):317–38.
w27x Mosmann TR, Sad S. The expanding universe of T-cell subsets:
Th1, Th2 and more. Immunol Today 1996;17(3):138–46.
w28x De Maeyer E, De Maeyer-Guignard J. Interferons. In: Thomson
A, editor. The cytokine handbook. San Diego: Academic Press,
1998. p. 491–516.
w29x Liu JH, Djeu JY. Role of cytokines in neutrophil functions. In:
Aggarwal BB, Puri RK, editors. Human cytokines: their role
in disease and therapy. Cambridge: Blackwell Science, Inc,
1995. p. 71–86.
w30x Song ZJ, Kharazmi A, Wu H, et al. Immunomodulatory
properties of ginseng: effects on Pseudomonas aeruginosa lung
infection. Clin Microbiol Infect 1999;5:5S37–5S38.
w31x Lim DS, Bae KG, Jung IS, Kim CH, Yun YS, Song JY. Anti-
septicaemic effect of polysaccharide from Panax ginseng by
macrophage activation. J Infect 2002;45(1):32–8.
w32x Yang JP, Yang GZ. Effects of ginsenoside on the central
neuropeptide Y and catecholamines in amputation-stressed
mice. Chin J Immunol 1993;9:36–8.
w33x Yang GZ, Bao T, Yu YL. Immunomodulating effects of
ginsenoside in vivo and in vitro. Commun Med Res
1987;16:220–1.
w34x See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of
echinacea and ginseng on natural killer and antibody-dependent
cell cytotoxicity in healthy subjects and chronic fatigue syn-
drome or acquired immunodeficiency syndrome patients.
Immunopharmacology 1997;35(3):229–35.
w35x Yun YS, Moon HS, Oh YR, Jo SK, Kim YJ, Yun TK. Effect
of red ginseng on natural killer cell activity in mice with lung
adenoma induced by urethane and benzo(a)pyrene. Cancer
Detect Prev Suppl 1987;1:301–9.
w36x Yun YS, Lee YS, Jo SK, Jung IS. Inhibition of autochthonous
tumor by ethanol insoluble fraction from Panax ginseng as an
immunomodulator. Planta Med 1993;59(6):521–4.
w37x Kim JY, Germolec DR, Luster MI. Panax ginseng as a potential
immunomodulator: studies in mice. Immunopharmacol Immu-
notoxicol 1990;12(2):257–76.
w38x Shen L, Zhang JT, Liu W. New evolvement on the study of
ginseng enhancing immunity. Traditional Chinese Herbal Med
1996;27:499–502.
w39x Johansen HK, Hougen HP, Rygaard J, Hoiby N. Interferon-
gamma (IFN-gamma) treatment decreases the inflammatory
response in chronic Pseudomonas aeruginosa pneumonia in
rats. Clin Exp Immunol 1996;103(2):212–8.
